Back to Aculeus
June 28, 2021
MELBOURNE — (28 June, 2021) — Aculeus Therapeutics has signed a service agreement with WEHI to evaluate the efficacy of the Aculeus drug candidate ACU-757 in models of COVID-19. WEHI is one of Australia’s leading medical research institutes. WEHI has been at the forefront of the global effort to tackle COVID-19, performing research in their high-level PC3 (BSL-3) facility.
The work is being conducted in the laboratory of Professor Marc Pellegrini (MBBS FRACP PhD) where the efficacy of ACU-757 will be evaluated in a preclinical model of COVID-19.
For more information on WEHI, visit: wehi.edu.au
